A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

← catalyst calendar

NCT06215118 · readout in 234 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →. With Bristol-Myers Squibb.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

87estimated

Sites

Countries

Australia, Canada, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-02-20

actual

When the study began enrolling

Primary completion

2027-04-10

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-03-09

estimated

The whole study's end, after follow-up

First posted

2024-01-22

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-10

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Multiple Myeloma

Interventions

Drug: Elranatamab — also filed as PF-06863135
Drug: Iberdomide — also filed as CC-220, BMS-986382

Primary outcomes

what the primary-completion date above is the date OF

Part 1: Number of participants with dose limiting toxicity (DLT)

measured Cycle 1, about 28 days

Part 2: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment

measured Assessed from baseline up to 90 days after last dose of study treatment

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed